Cargando…
Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991257/ http://dx.doi.org/10.1186/2051-1426-1-S1-O12 |
| _version_ | 1782312402638864384 |
|---|---|
| author | Kohrt, Holbrook Kowanetz, Marcin Gettinger, Scott Powderly, John Koeppen, Hartmut Sosman, Jeffrey A Cruz, Cristina Xiao, Yuanyuan Mokatrin, Ahmad Fine, Gregg Chen, Daniel S Hodi, F Stephen |
| author_facet | Kohrt, Holbrook Kowanetz, Marcin Gettinger, Scott Powderly, John Koeppen, Hartmut Sosman, Jeffrey A Cruz, Cristina Xiao, Yuanyuan Mokatrin, Ahmad Fine, Gregg Chen, Daniel S Hodi, F Stephen |
| author_sort | Kohrt, Holbrook |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991257 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912572014-05-05 Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 Kohrt, Holbrook Kowanetz, Marcin Gettinger, Scott Powderly, John Koeppen, Hartmut Sosman, Jeffrey A Cruz, Cristina Xiao, Yuanyuan Mokatrin, Ahmad Fine, Gregg Chen, Daniel S Hodi, F Stephen J Immunother Cancer Oral Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991257/ http://dx.doi.org/10.1186/2051-1426-1-S1-O12 Text en Copyright © 2013 Kohrt et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Kohrt, Holbrook Kowanetz, Marcin Gettinger, Scott Powderly, John Koeppen, Hartmut Sosman, Jeffrey A Cruz, Cristina Xiao, Yuanyuan Mokatrin, Ahmad Fine, Gregg Chen, Daniel S Hodi, F Stephen Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title | Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title_full | Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title_fullStr | Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title_full_unstemmed | Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title_short | Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1 |
| title_sort | intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to mpdl3280a, an engineered antibody against pd-l1 |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991257/ http://dx.doi.org/10.1186/2051-1426-1-S1-O12 |
| work_keys_str_mv | AT kohrtholbrook intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT kowanetzmarcin intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT gettingerscott intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT powderlyjohn intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT koeppenhartmut intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT sosmanjeffreya intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT cruzcristina intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT xiaoyuanyuan intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT mokatrinahmad intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT finegregg intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT chendaniels intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 AT hodifstephen intratumoralcharacteristicsoftumorandimmunecellsatbaselineandontreatmentcorrelatedwithclinicalresponsestompdl3280aanengineeredantibodyagainstpdl1 |